热门资讯> 正文
NLS Pharmaceuticals与Kadimastem合并获得纳斯达克批准
2025-10-23 19:20
- NLS Pharmaceutics (NASDAQ:NLSP) said that the company received an approval letter from the Nasdaq for the listing of its common shares and the trading of the company on the Nasdaq after completion of the merger with Kadimastem.
- The merger will be under NLS's new name, NewcelX Ltd., with its new trading symbol for its common shares, "NCEL".
- Accordingly, the closing of the merger is expected to close on October 30, 2025, with the transition to trading under the combined company's new name beginning October 31, 2025, subject to fulfillment of the remaining customary closing conditions.
More on NLS Pharmaceutics
- Financial information for NLS Pharmaceutics
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
